araag2/HINT huggingface dataset:
Clinical trial NCT00030966 (phase 3, status: completed)
Conditions: multiple sclerosis, relapsing-remitting
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: natalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MS as defined by McDonald et al, criteria, # 1- 4

          -  Between the ages of 18 and 55, inclusive

          -  Baseline EDSS score between 0.0 and 5.0, inclusive

          -  Have been treated with Avonex for at least the 12 months prior to randomization

          -  Have experienced at least one relapse (while on Avonex) within the 12 months prior to
             randomization.

          -  Cranial MRI scan demonstrating lesions consistent with MS.

          -  Have given written informed consent to participate in the study.

        Exclusion Criteria:

          -  Primary progressive, secondary progressive, or progressive relapsing MS.

          -  MS relapse has occurred within 50 days of randomization

          -  A clinically significant infectious illness within 30 days prior to randomization

          -  History of, or abnormal lab result, indicative of significant disease, that in the
             opinion of the investigator, would preclude the administration of a recombinant
             humanized antibody immunomodulating agent or Avonex for 116 weeks.

          -  History of severe allergic or anaphylactic reactions or known drug hypersensitivity.

          -  Unable to perform the Timed 25-Foot Walk, 9HPT and PASAT 3

          -  Abnormal blood tests at Screening Visit
Clinical trial NCT00519285 (phase 3, status: completed)
Conditions: prostatic neoplasms, neoplasm metastasis
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: aflibercept, placebo (for aflibercept), docetaxel, prednisone or prednisolone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically- or cytologically-confirmed prostate adenocarcinoma;

          -  Metastatic disease;

          -  Progressive disease while receiving hormonal therapy or after surgical castration;

          -  Effective castration.

        Exclusion Criteria:

          -  Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except
             adjuvant/neoadjuvant treatment completed >3 years ago;

          -  Prior treatment with Vascular Endothelial Growth Factor (VEGF) inhibitors or VEGF
             receptor inhibitors;

          -  Eastern Cooperative Oncology Group (ECOG) performance status >2.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT01327534 (phase 3, status: completed)
Conditions: myocardial infarction, stemi
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: prasugrel, clopidogrel
SMILES: CC(=O)OC1=CC2=C(CCN(C2)C(C(=O)C2CC2)C2=CC=CC=C2F)S1, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years and < 75 years

          -  Acute STEMI ≤ 12 h defined as 1. Angina or equivalent symptoms > 30 min and 2. ST
             elevation ≥ 2 leads (≥ 2 mm precordial leads, ≥ 1 mm limb leads) or ST depression ≥ 1
             mm precordial leads in posterior MI

          -  planned percutaneous coronary intervention

          -  legal capacity

          -  informed consent

          -  first medical contact in the prehospital setting or in a non-PCI hospital (this
             criterion was changed by a protocol amendment in autumn 2012 to "first medical contact
             in the prehospital setting, in a non-PCI hospital, or in a PCI-hospital, if the
             expected time until the start of the scheduled PCI is at least 20 minutes")

        Exclusion Criteria:

          -  Age ≥ 75 years

          -  Body weight < 60 kg

          -  Thrombolytic therapy within 24 hours before randomization

          -  Oral anticoagulation

          -  Known hemorrhagic diathesis

          -  History of Stroke or TIA

          -  Cardiogenic shock

          -  Evidence of an active gastrointestinal or urogenital bleeding

          -  Major surgery within 6 weeks

          -  Contraindication to prasugrel or clopidogrel

          -  Severe renal or hepatic insufficiency

          -  Contraindication to coronary angiography

          -  Planned administration of a GP IIb/IIIa-Inhibitor before angiography

          -  Pregnant or nursing (lactating) women

          -  Patients currently (within the last 10 days) treated with clopidogrel, prasugrel,
             ticlopidine, or ticagrelor

          -  Uncontrollable hypertension (blood pressure ≥ 200/110 mmHg in repeated measurements)

          -  Treatment with NSAIDs

          -  Participation in another clinical or device trial within the previous 30 days

          -  First medical contact in a PCI-hospital (this criterion was changed by a protocol
             amendment in autumn 2012 to "Expected time between administration of loading dose and
             start of PCI is < 20 minutes")
Clinical trial NCT00374036 (phase 3, status: completed)
Conditions: stomach cancer, neoplasm metastasis
ICD codes: D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ecc, folfiri
SMILES: FC1=CNC(=O)NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  age = 18 years old

          -  patients carrying a adenocarcinoma of the stomach or cardia histologically proven

          -  locally advanced tumour which may not be treated surgically or metastatic tumour

          -  the patients having a stenosante tumour responsible for a disphagy had to have a
             tumoral ablation or a prosthesis or a probe of food,

          -  measurable lesions according to criteria RECIST (specify measurement by spiral scanner
             of largest diameter of with less the one lesion of size higher than 1 cm) or
             appraisable but nonmeasurable (lesions < 1 cm, ascite, pleural effusion...)

          -  general state WHO < 2

          -  absence of insufficiency cardiac or coronary symptomatic

          -  absence of previous chemotherapy other that auxiliary stopped since more than 6 months

          -  filled questionnaires QLQ C30 and STO-22

          -  PNN = 1500/mm3, haemoglobin ≥ 10g/dl, plates= 100 000/mm3

          -  creatinin ≤ 110 micromol/l

          -  bilirubin ≤ 35 micromol/l

        Exclusion Criteria:

          -  disphagy or intestinal obstruction incompatible with a treatment per os or by a probe
             of food

          -  pregnant or nursing woman

          -  previous of cardiac toxicity to the 5FU or to the anthracyclines

          -  radiotherapy less than 3 weeks before inclusion, whatever the site

          -  other evolutionary cancer threatening the short-term life

          -  metastasis cerebral or méningée known (without obligation to seek it)

          -  impossibility of regular follow-up for psychological, social, family or geographical
             reasons
Clinical trial NCT00704730 (phase 3, status: completed)
Conditions: thyroid cancer
ICD codes: C73, D34, D44.0, Z85.850
Drugs: xl184, placebo
SMILES: COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The subject has a histologically confirmed diagnosis of MTC that cannot be removed by
             surgery, is locally advanced, or has spread in the body.

          -  The subject is at least 18 years old.

          -  The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.

          -  The subject has documented worsening of disease (progressive disease) at screening
             compared with a previous CT scan or MRI image done within 14 months of screening.

          -  The subject has recovered from clinically significant adverse events (side effects)
             due to any other medications that were administered prior to randomization.

          -  The subject has adequate organ and bone marrow function.

          -  Subjects who are sexually active (male and female) must agree to use medically
             accepted methods of contraception during the course of the study and for 3 months
             following discontinuation of study treatments.

          -  The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an
             early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and
             currently has no evidence of malignancy (unless non-melanoma skin cancer or an early
             form of cervical cancer).

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             screening.

        Exclusion Criteria:

          -  The subject has received prior treatment for their cancer within 4 weeks of
             randomization (6 weeks for nitrosoureas or mitomycin C).

          -  The subject has received radiation to ≥ 25 % of bone marrow.

          -  The subject has received treatment with other investigational agents (unapproved
             therapies) within 4 weeks of randomization.

          -  The subject has received treatment with XL184.

          -  The subject has brain metastases or spinal cord compression, unless completed
             radiation therapy ≥ 4 weeks prior to randomization and stable without steroid and
             without anti-convulsant treatment for ≥ 10 days.

          -  The subject has a history of clinically significant episodes of vomiting blood or a
             recent history of vomiting > 2.5 mL (about 1/2 teaspoon) of red blood.

          -  The subject has serious illness other than cancer.

          -  The subject is pregnant or breastfeeding.

          -  The subject has an active infection requiring ongoing treatment.

          -  The subject is incapable of understanding and complying with the protocol or unable to
             provide informed consent.
Clinical trial NCT00132678 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: risperdal consta, placebo
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of bipolar 1 disorder, currently experiencing a mixed or manic episode or
             stable

          -  Two or more bipolar mood episodes in the last 2 years excluding current episode

          -  Negative pregnancy test

        Exclusion Criteria:

          -  History of > than 4 mood episodes a year during the last two years

          -  patients experiencing a depressive episode

          -  History of antisocial or borderline personality illness

          -  Has unstable or serious general medical illness

          -  Has received medications disallowed by study criteria.
Clinical trial NCT00003803 (phase 3, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cisplatin, gemcitabine hydrochloride
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer

               -  Stage I, II, III (T1-4, N0-3, M0)

                    -  No metastases to supraclavicular, contralateral hilar, or contralateral
                       scalene lymph nodes

               -  Medically inoperable or unresectable

          -  No pleural or pericardial effusion (except with repeated negative cytology)

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  ECOG 0 or 1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 4,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 6.8 g/dL

          -  No hemoptysis causing a decrease of hemoglobin of 1 g/dL or more within 24 hours

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine no greater than 1.25 times normal OR

          -  Creatinine clearance greater than 70 mL/min

        Cardiovascular:

          -  No evidence of heart failure

          -  No myocardial infarction within the past 6 months

          -  No superior vena cava syndrome

        Pulmonary:

          -  FEV1 at least 1 L

          -  No pre-existing fibrotic lung disease

          -  No postobstructive pneumonia preventing exact delineation of tumor volume

          -  Diffusion capacity at least 60%

        Other:

          -  No weight loss of more than 10% in the past 3 months

          -  No uncontrolled infection

          -  No serious medical risk factors involving any of the major organ systems that would
             preclude adherence to the study treatment schedule

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunotherapy

        Chemotherapy:

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy to the chest

          -  Maximum length of the esophagus receiving 40 Gy no greater than 18 cm

          -  Maximum length of the esophagus receiving 66 Gy no greater than 12 cm

          -  Must limit the spinal cord dose to a maximum of 50 Gy

          -  Must be able to exclude 25% of the heart from the boost volume

        Surgery:

          -  Not specified

        Other:

          -  No other concurrent experimental medications
Clinical trial NCT00634309 (phase 3, status: completed)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: candesartan, placebo
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 or above

          -  Congestive Heart Failure with symptoms for more than 4 weeks before starting study

          -  Provision of informed consent

        Exclusion Criteria:

          -  Current low blood pressure with symptoms

          -  Liver disease considered significant by the study doctor

          -  Pregnant or lactating females
Clinical trial NCT00299546 (phase 3, status: completed)
Conditions: arthritis, rheumatoid
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients have a diagnosis of rheumatoid arthritis (RA) (according to the revised 1987
             criteria of the ACR) for at least 3 months prior to screening

          -  Have active RA as defined by persistent disease activity with at least 4 swollen and 4
             tender joints, at the time of screening and baseline

          -  Must have been previously treated with at least one dose of etanercept, adalimumab, or
             infliximab

          -  If currently using methotrexate, sulfasalazine and/or hydroxychloroquine must have
             tolerated these agents for at least 12 weeks and be on a stable dose for at least 4
             weeks prior to the first administration of study agent

          -  If using NSAIDs or other analgesics must be on a stable dose for at least 2 weeks
             prior to the first administration of study agent

          -  If using oral corticosteroids must be on a stable dose equivalent to <= 10 mg of
             prednisone/day for at least 2 weeks prior to first administration of study agent

          -  Are considered eligible according to specified tuberculosis (TB) screening criteria.

        Exclusion Criteria:

          -  Patients cannot have other inflammatory diseases other than RA that might interfere
             with the evaluation of the benefit of golimumab therapy

          -  No history of treatment with natalizumab, rituximab or cytotoxic agents

          -  No history of demyelinating diseases such as multiple sclerosis or optic neuritis or
             of concurrent congestive heart failure (CHF), lymphoproliferative disease, known
             malignancy or history of malignancy within the previous 5 years (with the exception of
             a nonmelanoma skin cancer that has been treated with no evidence of recurrence)

          -  No history of, or ongoing, chronic or recurrent infectious disease

          -  No serious infection within 2 months prior to first administration of study agent.
Clinical trial NCT00062556 (phase 3, status: completed)
Conditions: intermittent claudication, peripheral vascular disease
ICD codes: I70.211, I70.212, I70.213, I70.218, I70.219, I70.611, I70.612, I73.9, I73.89
Drugs: niacin extended release and lovastatin tablets
SMILES: OC(=O)C1=CN=CC=C1
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Men & women at least 40 years of age or older. Women must not be pregnant nor
             breast-feeding & not planning to become pregnant or to breast-feed.

          -  History of IC of the lower extremities which has been present for at least 6 months
             with no change in symptoms in the previous 3 months prior to screening.

          -  LDL-C of < 160 mg/dL and Triglycerides < 800mg/dL.

        EXCLUSION CRITERIA:

          -  Severe neuropathy

          -  Gross obesity (BMI ≥ 40)

          -  Presence of critical limb ischemia defined as ischemic rest pain, gangrene,
             ulceration, or pending amputation of a lower extremity due to severe PAD.

          -  Surgical intervention to alleviate symptoms of claudication within 6 months or
             endovascular interventions within 3 months

          -  Documented CAD taking any cholesterol-modifying agent

          -  Systolic blood pressure ≥ 160 mmHg &/or diastolic blood pressure ≥ 95 mmHg

          -  Presence of clinically significant laboratory test abnormalities for liver or renal
             function tests or HgbA1C.

          -  History of alcohol abuse or currently drinks alcohol in excess.
Clinical trial NCT00690794 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: travoprost ophthalmic solution 0.004% with sofzia® preservative system (travatan z®), latanoprost ophthalmic solution 0.005% (xalatan®)
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(=C1)C(F)(F)F, CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  18 years or older.

          -  Ocular Surface Disease Index (OSDI) score and corneal fluorescein staining score as
             specified in protocol.

          -  Diagnosis of open-angle glaucoma or ocular hypertension in at least one eye.

          -  Intraocular pressure (IOP) controlled with latanoprost 0.005% (XALATAN®) for at least
             one continuous month prior to Visit 1.

          -  Willing and able to discontinue use of any topical ocular medication other than the
             study medication for the duration of the study, including artificial tears.

          -  Best corrected visual acuity of -0.6 logarithm of the Minimum Angle of Resolution
             (logMAR) or better in each eye.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Any medical condition (systemic or ophthalmic) that may preclude safe administration
             of the test article.

          -  Use of contact lenses within 30 days of Visit 1.

          -  Use of contact lenses during the study.

          -  Participation in an investigational drug or device study within 30 days of entering
             this study.

          -  Other protocol-defined exclusion criteria may apply.
Clinical trial NCT01368081 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: metformin, bi 10773, placebo (low dose), bi 10773, placebo (high dose)
SMILES: CSCC[C@H](N)C(O)=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  .Diagnosis of type 2 diabetes mellitus prior to informed consent

          -  Male and female patients, on diet and exercise regimen, who are pre-treated with one
             of the following oral antidiabetic drugs: sulfonylurea, glinide, biguanide,
             Alpha-glucosidase inhibitor (a-GI), dipeptidyl peptidase-IV (DPP-IV) inhibitor or
             thiazolidinedione

          -  glycosylated haemoglobin (HbA1c) at Visit 1: >=7.0 to =<10.0% (national
             glycohemoglobin standardization program)

        Exclusion criteria:

          -  Uncontrolled hyperglycaemia with a glucose level >240 mg/dL (>13.3 mmol/L)

          -  Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks
             prior to informed consent

          -  Indication of liver disease, defined by serum levels of either alanine transaminase
             (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper
             limit of normal (ULN)